Regulatory Services: Submission Filing

By Anne Tomalin |

A few key details to keep in mind prior to filing your submissions. Hear from our regulatory expert Anne Tomalin, Vice President, Quality, Regulatory and Safety as she reviews the required format for your submission, foreign reviews and whether submissions can be updated after filing.

Video Transcript:

The format for a new drug submission in Canada is the ICH format, the common technical document, and you are required to submit that as an eCTD, or an Electronic Common Technical Document. We follow ICH requirements for Modules 2, 3, 4, and 5. For Module 1, there is a very specific guideline that details what is required from a Canadian perspective in Module 1. 

So clients frequently ask if a foreign review can be accepted in Canada. The answer is no. Health Canada does like to receive copies of foreign reviews, if they're available. However, Canada is an independent country, and Health Canada is required to make the decision about approval independently, and cannot simply accept an approval done by another country.

After a file has – a new drug submission has been filed in Canada you cannot update that file with the exception of safety. If a safety issue develops after the NDS has been filed, then you can update the submission. However, the safety issue has to be sufficient in degree that the product monograph is required to be updated. If you're not required to update the product monograph, then you cannot update the submission.

Learn more

Connect With an Expert

Find out how Innomar Strategies can help you prepare for commercialization success in the Canadian market. 

Contact us

About the Author

Anne Tomalin

Anne Tomalin

Vice President
Quality, Regulatory & Safety
Anne Tomalin, BA, B.Sc., joined Innomar in 2018 following the acquisition of TPIreg. With over 40 years of experience in the pharmaceutical industry, she is a recognized leader in Regulatory Affairs, Quality Assurance, and Safety. As the founder and president at TPIreg, she consulted with pharmaceutical companies in Canada and internationally and is a recognized leader and speaker on regulatory, including biological products and rare disease. At Innomar she strategically and operationally leads a diverse team focused on Regulatory Affairs (RA), QA (GMP focused), and Safety (medical information and pharmacovigilance) to optimize client launch planning and operations throughout the product lifecycle.  
View Bio